DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease

• Sara E. F. Kost,
• Ali Saleh,
• Shek H. Yuan,
• Bozena Kuzio,
• Spencer B. Gibson,
• Lin Yang,
• Versha Banerji,
• James B. Johnston,
• Sachin Katyal

Affiliations

Sara E. F. Kost

CancerCare Manitoba Research Institute, CancerCare Manitoba

Ali Saleh

CancerCare Manitoba Research Institute, CancerCare Manitoba

Shek H. Yuan

CancerCare Manitoba Research Institute, CancerCare Manitoba

Bozena Kuzio

CancerCare Manitoba Research Institute, CancerCare Manitoba

Spencer B. Gibson

CancerCare Manitoba Research Institute, CancerCare Manitoba

Lin Yang

Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba

Versha Banerji

CancerCare Manitoba Research Institute, CancerCare Manitoba

James B. Johnston

CancerCare Manitoba Research Institute, CancerCare Manitoba

Sachin Katyal

CancerCare Manitoba Research Institute, CancerCare Manitoba